Atossa Therapeutics updates shareholders on clinical progress, highlighting advancements in (Z)-endoxifen for breast cancer prevention and treatment.
Quiver AI Summary
Atossa Therapeutics, Inc. has provided a shareholder update highlighting significant progress in their clinical programs, particularly with their therapy (Z)-endoxifen for breast cancer prevention and treatment. In 2024, Atossa completed the KARISMA-Endoxifen Phase 2 study, which showed that low doses of (Z)-endoxifen effectively reduced mammographic breast density, a risk factor for breast cancer, at tolerable levels. Additionally, progress in the EVANGELINE trial demonstrated preliminary success in tumor suppression among women with estrogen receptor-positive breast cancer. The company is also advancing two I-SPY studies involving (Z)-endoxifen and reported a strong financial position to support ongoing research. Looking ahead to 2025, Atossa aims to expedite clinical trials for (Z)-endoxifen, enhance collaborations, and broaden its impact in breast cancer treatment.
Potential Positives
- Completion of the KARISMA-Endoxifen Phase 2 Study demonstrated significant reductions in mammographic breast density (MBD) for (Z)-endoxifen, highlighting its potential as a promising alternative to tamoxifen at lower doses.
- Advancements in the EVANGELINE trial showed promising initial results for (Z)-endoxifen as a neoadjuvant treatment in premenopausal women with ER+/HER2- breast cancer, emphasizing its effectiveness and tolerability.
- Expansion of the intellectual property portfolio with two additional U.S. patents for (Z)-endoxifen reinforces Atossa's leadership and the novelty of its therapeutic approach.
- Strong financial position enables efficient funding of research and development efforts, ensuring operational stability and continued progress toward clinical trial goals.
Potential Negatives
- Despite promising results from various studies, the company continues to operate in a high-risk and uncertain regulatory environment, which could impact the future of their clinical trials and product approvals.
- There is no guarantee that the anticipated data from ongoing clinical trials, particularly the I-SPY studies, will meet expectations, potentially delaying the approval and market availability of (Z)-endoxifen.
- Atossa's forward-looking statements highlight potential challenges in achieving financial stability, including the need to raise capital and uncertainties surrounding operational compliance and regulatory requirements.
FAQ
What are the key achievements of Atossa Therapeutics in 2024?
Atossa Therapeutics completed the KARISMA-Endoxifen Phase 2 Study, demonstrating significant reductions in mammographic breast density with (Z)-endoxifen.
How is (Z)-endoxifen being tested in clinical trials?
(Z)-endoxifen is being evaluated in multiple Phase 2 trials, including the EVANGELINE study for premenopausal women with ER+/HER2- breast cancer.
What are the potential benefits of (Z)-endoxifen?
(Z)-endoxifen offers a promising therapy for women with dense breast tissue, providing better tolerability and significant reductions in breast cancer risk factors.
How is Atossa ensuring the viability of its therapies?
Atossa has strengthened its intellectual property portfolio, securing additional U.S. patents for (Z)-endoxifen, enhancing the value of its pipeline.
What is Atossa's upcoming focus for 2025?
In 2025, Atossa aims to advance (Z)-endoxifen into registrational trials and expand collaborations to improve global access to this therapy.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ATOS Hedge Fund Activity
We have seen 35 institutional investors add shares of $ATOS stock to their portfolio, and 30 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NORTHERN TRUST CORP added 686,991 shares (+257.1%) to their portfolio in Q3 2024, for an estimated $1,044,226
- BLACKROCK, INC. added 470,575 shares (+5.1%) to their portfolio in Q3 2024, for an estimated $715,274
- RENAISSANCE TECHNOLOGIES LLC removed 240,840 shares (-15.5%) from their portfolio in Q3 2024, for an estimated $366,076
- GOLDMAN SACHS GROUP INC added 146,463 shares (+142.7%) to their portfolio in Q3 2024, for an estimated $222,623
- BARCLAYS PLC added 123,683 shares (+280.9%) to their portfolio in Q3 2024, for an estimated $187,998
- JANE STREET GROUP, LLC removed 123,146 shares (-47.3%) from their portfolio in Q3 2024, for an estimated $187,181
- VANGUARD GROUP INC added 112,419 shares (+1.7%) to their portfolio in Q3 2024, for an estimated $170,876
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) --
Atossa Therapeutics, Inc.
(Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today announced that Steven Quay, M.D., Ph.D., Chairman and CEO, has issued a Letter to Shareholders providing an update on the Company’s clinical programs and recent events. The full text of the letter follows:
To our valued shareholders,
As we reflect on 2024, I am proud to share the remarkable progress Atossa Therapeutics has made in advancing our mission to address significant unmet needs in breast cancer prevention and treatment. Last year was vital for Atossa as we continued to demonstrate the broad utility of (Z)-endoxifen as an innovative therapy that has the potential to transform the breast cancer treatment landscape.
Key Milestones of 2024
Completion of the KARISMA-Endoxifen Phase 2 Study
- One of the most significant milestones this year was the completion and announcement of results from our phase 2
KARISMA-Endoxifen Study
. This study evaluated the ability of low doses of (Z)-endoxifen to reduce mammographic breast density (MBD), an independent risk factor for breast cancer that also complicates early tumor detection.
The study demonstrated significant reductions in MBD, with decreases of 17.3 percentage points in the 1 mg arm (p<0.01) and 23.5 percentage points in the 2 mg arm (p<0.01), compared to a negligible change in the placebo group. These reductions are comparable to those observed with tamoxifen, a commonly prescribed therapy, but were achieved at much lower doses of (Z)-endoxifen, offering improved tolerability. Both doses were well tolerated, with the 1 mg arm showing a safety profile similar to placebo.
Almost half of the women in the world over the age of 40 have dense breasts and this condition not only makes mammograms far less effective, but it also significantly increases the likelihood that a woman will develop breast cancer in her lifetime. This achievement highlights (Z)-endoxifen’s potential as a promising therapy for women with dense breast tissue, offering a safer, better tolerated alternative to tamoxifen. By reducing MBD, (Z)-endoxifen may play a vital role in lowering breast cancer risk while enabling earlier and more effective detection through imaging. These results underscore our commitment to delivering innovative therapies that not only address the challenges of cancer treatment but may also offer preventative solutions that align with women’s needs.
Advancements in the EVANGELINE Trial
- Our
EVANGELINE
trial has also made substantial progress this year. This phase 2 non-inferiority study aims to evaluate (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with estrogen receptor-positive (ER+)/ Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
The study includes a pharmacokinetic (PK) run-in phase, which has shown promising initial results. The primary endpoint was achieved in the run-in phase as 50 percent of patients (3/6) in the group receiving 80 mg of (Z)-endoxifen with goserelin met the target steady-state plasma concentrations (Css) of 500–1000 ng/mL. Approximately 38 percent of patients (3/8) in the 80 mg/day (Z)-endoxifen only group reached the target Css levels. The average plasma Css level for all patients receiving 80 mg/day of (Z)-endoxifen was 484 ng/mL. Tissue Css levels were also evaluated, in line with the updated trial protocol, and we were very excited about the results which showed that the 80 mg/day dose in both treatment arms achieved tissue Css levels
more than double
that of plasma levels, exceeding the 500 ng/g target in 90 percent of patients, a level sufficient to target PKCβ.
Importantly, significant tumor suppression was also observed across all dosing levels, with or without ovarian function suppression (OFS). The 4-week Ki-67 ≤10 percent response rate was consistently above 85 percent across dose levels, regardless of the presence of OFS. These findings suggest that (Z)-endoxifen monotherapy could be a more tolerable alternative to the current standard of care, which often results in significant side effects and poor compliance. As we move into the randomized portion of the trial, we remain focused on building the evidence to support (Z)-endoxifen as a more tolerable, effective option for this patient population.
Advancements in I-SPY 2 Endocrine Optimization Pilot (EOP)
- Atossa currently has two I-SPY 2 studies underway investigating (Z)-endoxifen neoadjuvant activity as a monotherapy and in combination with abemaciclib (VERZENIO
®
), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company.
A preliminary data analysis from the monotherapy arm of this pilot, which included 20 women with ER+/HER2- breast cancer who received 10mg of (Z)-endoxifen orally once daily for six cycles (each cycle = 28 days), showed that (Z)-endoxifen met the primary endpoint with 95 percent (19/20 patients) receiving greater than 75 percent of planned treatment.
Impressively, the data also demonstrated (Z)-endoxifen activity in rapidly reducing key biomarkers such as Ki-67 by 69 percent from baseline and a 30.4 percent reduction in functional tumor volume (FTV) from baseline after only three weeks of treatment.
Once again, (Z)-endoxifen was found to be well tolerated in this study with the most common side effects being mild, including hot flushes, insomnia, and fatigue. No dose reductions or discontinuations due to treatment related adverse events were observed in this study. We look forward to sharing surgical Ki-67 values and 24-wk imaging when this data becomes available.
Last year, we also announced that we initiated a new combination therapy arm of the I-SPY 2 EOP evaluating (Z)-endoxifen in combination with abemaciclib, as a neoadjuvant treatment in high-risk women with newly diagnosed ER+/HER2- breast cancer. These patients have substantial risk for recurrence, often after five years, and need novel treatments that address the risk of recurrence and are more effective and tolerable than the current standard of care.
Data from this study, anticipated in 2026, is expected to further validate the growing body of evidence that (Z)-endoxifen is well-tolerated and highly efficacious in both premenopausal and postmenopausal breast cancer patients.
Expansion of Intellectual Property Portfolio
- In addition to advancing our clinical programs, we have continued to strengthen our intellectual property portfolio, ensuring the long-term viability and protection of our therapies. This year, we secured two additional U.S. patents for (Z)-endoxifen, further solidifying our leadership in this field. These efforts not only validate the novelty of our approach but also enhance the value of our pipeline.
Financial Stability and Growth
- Our strong cash position and disciplined financial planning have allowed us to efficiently fund our research and development efforts while maintaining operational stability. This financial prudence ensures we can continue driving our programs forward with confidence.
Key Learnings About the Broad Applicability of (Z)-Endoxifen
in 2024 will drive registrational trial design in 2025 - 2024 provided valuable insights into the broad applicability of (Z)-endoxifen in the fight against breast cancer. Beyond its effectiveness in reducing mammographic breast density and serving as a promising neoadjuvant therapy, our research has revealed its potential across nearly all stages of breast cancer care. By demonstrating efficacy at lower doses, (Z)-endoxifen potentially opens the door for safer, more tolerable options that can enhance patient compliance through better tolerance. Its versatility suggests potential applications not only for women at high risk of breast cancer but also for those seeking alternatives to existing treatments.
Looking Ahead to 2025
As we enter 2025, we are excited to build on this momentum. Our focus remains on:
Identifying key opportunities to advance (Z)-endoxifen into registrational clinical trials with the goal of advancing (Z)-endoxifen to the market in the quickest way possible.
This is our company’s top priority, and we commit to communicating our progress on this goal in the first quarter of this year.
Amplifying our ongoing business development efforts to ensure women globally have the opportunity to benefit from (Z)-endoxifen.
Deepening collaborations with industry leaders and advocacy groups to broaden the impact of our work.
Extending our track record of financial strength that will position us to support our long-term growth.
On behalf of everyone at Atossa, I want to express my deepest gratitude for your continued trust and support. Your partnership is invaluable as we work toward a future where more women can lead healthier, longer lives free from the burden of breast cancer. Together, we are driving meaningful change and advancing our shared mission to transform the landscape of breast cancer treatment and prevention.
Sincerely,
Steven Quay, M.D., Ph.D.,
Chairman and Chief Executive Officer
Atossa Therapeutics, Inc.
About (Z)-Endoxifen
(Z)-endoxifen is one of the most potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition and may cause estrogen receptor degradation. It has also been shown to have efficacy in the setting of patients with tumor resistance to other hormonal treatments. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCβ1, a known oncogenic protein, at clinically attainable blood concentrations. Finally, (Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen.
Atossa is developing a proprietary oral formulation of (Z)-endoxifen that is encapsulated to bypass the stomach, as acidic conditions in the stomach convert a significant proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa’s (Z)-endoxifen has been shown to be well tolerated in Phase 1 studies and in a small Phase 2 study of women with breast cancer. (Z)-endoxifen is currently being studied in five Phase 2 trials: one in healthy women with measurable breast density, one in women diagnosed with ductal carcinoma in situ, and three other studies including the EVANGELINE study and two I-SPY studies in women with ER+/HER2- breast cancer. Atossa’s (Z)-endoxifen is protected by four issued U.S. patents and numerous pending patent applications.
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. For more information, please visit
www.atossatherapeutics.com
.
FORWARD LOOKING STATEMENTS
This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other comparable words. All statements made in this press release that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the expected design and enrollment of trials and timing of data and related publications, and the potential milestones and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to remain compliant with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.
Contact:
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
